Cure8 research brief
Cure8 research brief
Measures used in trials and care often miss what patients value most — daily function and quality of life. Learning from IBD and RA could lead to asthma outcome measures and trials that reflect patient priorities, which matters to anyone receiving or studying biologic treatments.
Clinicians and researchers working on severe asthma and outcome measurement; patients and patient advocates interested in PROMs and trial design; regulators and industry designing clinical trials for biologics.
This article (abstract) argues that severe asthma should adopt patient-centred outcome measurement approaches used in rheumatoid arthritis and inflammatory bowel disease — specifically incorporating PROMs and composite scores into trials and routine care.
It highlights initiatives (COMSA, CONFiRM) and past efforts in RA (OMERACT) and IBD (STRIDE) as precedents, and calls for electronic data collection, regulatory acceptance of PROMs, and authentic patient partnership.
Structured content depth is “abstract” — the classification and curator note are grounded in the provided abstract rather than a full-paper review. The article uses IBD and RA as examples of fields that integrated PROMs; it is an argument/editorial-style piece advocating measurement changes rather than reporting new trial results.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.